参考文献

[1]Gouw S C,Vanden Berg H M.The multifactorial etiology of inhibitor development in hemophil -ia:genetics and environment[J].Semin Thromb Hemost,2009,35:723-734.

[2]Wang X F,Zhao Y Q,Yang R C,et al.The prevalence of factor Ⅷ inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia[J].Hemophilia,2010,16:632-639.

[3]Ghosh K,Shetty S.Immune response to F Ⅷ in hemophilia A:an overview of risk factors[J].Clin Rev Immunol,2009,37:58-66.

[4]Wagner N,Rotthauwe H W.Hepatitis C contributes to lixer disease in children and adolescents with hemophilia[J].Clin Pediatr,1994,206(1):40-44.

[5]Santagosino E,Colombo M,Cultraro D,et al.High prevalence of serum cryoglobulins in multi -transfused hemophilic patients with chronic hepatitis C[J].Blood,1998,92(2):516.

[6]阮长庚,吴德沛,李建勇,等.现代血液病诊断治疗学[M].合肥:安徽科学技术出版社,2007:176-248.(https://www.daowen.com)

[7]Howes J,Smith R,Helmer S,et al.Complications of recombinant activated human coagulation factorⅦ[J].Am J Surg,2009,198(6):895-899.

[8]AL-Ruzzeh,Navia J L.“off-label”role of recombinant factor Ⅶ a in surgery:is the problem deficient evidence or defective concept?[J].J Am Coll Surg,2009,209(5):659-667.

[9]Liu S X,Jiang L,Liang X,et al.Study on graded therapy of hemophilic arthritis by integrative traditional Chinese and Western medicine[J].Chin J Integr Med,2007,13(4):301-305.

[10]Liu S X,Jiang L, Liu Y G, et al.Study on the efficacy and safety of Xueyou Mixture in treating hemophilia[J].Chin J Integr Med,2007,13(2):141-141.

[11]刘陕西,江琳,孔伟伟,等.100例血友病资料分析新概念 [J].中国实用医药,2007,2(24):166-69.